Cell line · CVCL_0622
MDA-MB-435S
Cancer cell line, Homo sapiens. Amelanotic melanoma. Cellosaurus records it as contaminated. 23 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. MDA-MB-435S. Cell lines, record CVCL_0622. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0622
On this page
Cell line
As Cellosaurus gives it.
- Name
- MDA-MB-435S
- Accession
- CVCL_0622
- RRID
- RRID:CVCL_0622
- Synonyms
- MDA-MB-435s, MDA-MB-435 S, MDA-MB-435-S, MDAMB435S, BrCL15
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 33Y
- Category
- Cancer cell line
- Diseases
- Amelanotic melanoma (NCIt C3802)
- Derived from
- Right buttock, hypodermis (metastatic)
- Parent
- MDA-MB-435 (CVCL_0417)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems1
| Problem | Cellosaurus's note |
|---|---|
| Contaminated | Parent cell line (MDA-MB-435) has been shown to be a M14 derivative. |
Source Cellosaurus
Papers23
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Ceritinib induces ferroptosis via TRIM21-mediated GLUT1 ubiquitination and AMPK-driven metabolic reprogramming in breast cancer. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the tumor cell-intrinsic ITGB2 axis inhibits melanoma progression. | Mol Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer. | Cancer Discov | 2024 | Its Methods give the RRID and name the line | PubMed | |
| AEP-cleaved DDX3X induces alternative RNA splicing events to mediate cancer cell adaptation in harsh microenvironments. | J Clin Invest | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Nucleolin Overexpression Predicts Patient Prognosis While Providing a Framework for Targeted Therapeutic Intervention in Lung Cancer. | Cancers (Basel) | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line. | Int J Cancer | 2018 | Cellosaurus cites it | PubMed | |
| TGF-β reduces DNA ds-break repair mechanisms to heighten genetic diversity and adaptability of CD44+/CD24- cancer cells. | Elife | 2017 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 23
See all 23 papersRelatives3
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Parent | MDA-MB-435 | CVCL_0417 | Has a recorded problem | Cell lines |
| Derived from it | MDA-MB-435S/1 | CVCL_A6LJ | Has a recorded problem | Cell lines |
| Derived from it | MDA-MB-435s-mKate2 | CVCL_5T70 | Has a recorded problem | Cell lines |
Cell banks6
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | HTB-129 | ATCC | |
| BCRJ | 0165 | BCRJ | |
| CCTCC | GDC0053 | Cellosaurus | |
| CLS | 300277 | CLS | |
| ICLC | HTL03006 | ICLC | |
| KCB | KCB 200773YJ | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0622
GET https://conductscience.org/api/cell-lines/v1/CVCL_0622/papers?page=2